Eliquis Bleeding Risks Similar to Xarelto, Pradaxa
Eliquis (apixaban) is part of a controversial group of new anticoagulant, which have been introduced in recent years as replacements for warfarin. Due to alarming bleeding problems linked to earlier members of this new class, the lawyers at Saiontz & Kirk, P.A. have pursued Xarelto lawsuits and Pradaxa lawsuits for individuals and family members nationwide. However, it appears that the bleeding risks from Eliquis side effects are just as dangerous, and inadequate warnings were also provided by the drug makers.
Known as novel oral anticoagulants (NOACs), Eliquis, Xarelto and Pradaxa have been aggressively marketed for prevention of strokes and blood clots among individuals with non-valvular atrial fibrillation and other conditions. However, unlike warfarin, which has been the go-to anticoagulant for decades, all three drugs were introduced without a safe and effective reversal agent. As a result, doctors have been unable to stop or control many severe bleeding problems with Eliquis, Xarelto and Pradaxa.
In addition to pursuing failure to warn cases against the makers of Xarelto and Pradaxa, our lawyers are also reviewing potential Eliquis lawsuits for individuals nationwide. All cases are pursued under a contingency fee agreement, which means that there are never any out of pocket costs to hire our law firm and we receive no attorney fees unless a recovery is obtained. Request a free consultation and claim evaluation.
Eliquis Safety Problems
Did You or a Loved One Suffer a Bleeding Injury on Eliquis, Xarelto or Pradaxa?
A number of studies have been conducted comparing Eliquis to Pradaxa and Xarelto. They have, overall, found that the drugs carry a similar risk profile.
In December 2013 in the medical journal Thrombosis, researchers from Spain determined that all three drugs seemed “no more effective than warfarin” at preventing nonhemorrhagic strokes and systemic embolic events, while providing a slight decrease in the risk of intracranial bleeding.
However, a study published this year in the Journal of Thrombosis and Thrombolysis by researchers from the Memorial Sloan-Kettering Cancer Center found that despite no difference in the risk of recurring venous thromboembolism and death rate could be found between the three drugs, Eliquis appeared to be associated with a slightly lower risk of bleeding.
Most of the studies have focused on comparing the drugs to warfarin, however, and most have found that they carry similar safety profiles. Whereas warfarin has a known and effective reversal agent to quickly stop bleeding events, Eliquis, Pradaxa and Xarelto were introduced without such an antidote and without warnings for doctors about the uncontrollable bleeding risk.
Pradaxa, being the first on the market, was the first to reach blockbuster status. But as the number of users increased, so did the number of adverse events reported to the FDA. Concerns over Pradaxa bleeding events led to its decline, and Xarelto quickly replaced it as the leading NOAC.
Since Xarelto’s popularity increased, it has surpassed Pradaxa in both sales and the number of adverse events reported, suggesting that the more the drugs are used in the wider population, the more apparent the bleeding problems become.
Eliquis now appears to be on its way to catching up with, and potentially surpassing, Xarelto, with sales approaching blockbuster status.
Eliquis Bleeding Injury Cases
It appears that the bleeding risk with Eliquis and Pradaxa and Xarelto is similar. All of these new drugs have been associated with uncontrollable bleeding and hemorrhaging events due to the lack of a reversal agent and failure of the drug makers to provide adequate warnings and safety information.
The manufacturers failed to adequately warn the medical community and patients of the Eliquis bleeding injury risks, and about the lack of an antidote to control such bleeding. It appears they placed profits ahead of patient safety by not first developing a reversal agent to prevent deadly Eliquis hemorrhaging before unleashing the drug onto the market.
The Eliquis injury lawyers at Saiontz & Kirk are reviewing potential claims for individuals nationwide who have suffered bleeding injuries while taking the drug, and wrongful death lawsuits for those who have lost family members due to uncontrolled bleeding events.